145 related articles for article (PubMed ID: 25357107)
1. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer.
Yu JL; Lv P; Han J; Zhu X; Hong LL; Zhu WY; Wang XB; Wu YC; Li P; Ling ZQ
Arch Pathol Lab Med; 2014 Nov; 138(11):1466-73. PubMed ID: 25357107
[TBL] [Abstract][Full Text] [Related]
2. Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer.
Wu YC; Lv P; Han J; Yu JL; Zhu X; Hong LL; Zhu WY; Yu QM; Wang XB; Li P; Ling ZQ
Int J Clin Exp Pathol; 2014; 7(4):1553-62. PubMed ID: 24817951
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer.
Deng J; Liang H; Ying G; Dong Q; Zhang L; Yu J; Fan D; Hao X
J Am Coll Surg; 2014 Nov; 219(5):904-13. PubMed ID: 25260683
[TBL] [Abstract][Full Text] [Related]
5. Circulating methylated THBS1 DNAs as a novel marker for predicting peritoneal dissemination in gastric cancer.
Hu XY; Ling ZN; Hong LL; Yu QM; Li P; Ling ZQ
J Clin Lab Anal; 2021 Sep; 35(9):e23936. PubMed ID: 34390026
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients.
Łukaszewicz-Zając M; Mroczko B; Guzińska-Ustymowicz K; Pryczynicz A; Gryko M; Kemona A; Kędra B; Szmitkowski M
Adv Med Sci; 2013; 58(2):235-43. PubMed ID: 24384769
[TBL] [Abstract][Full Text] [Related]
7. Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer.
Wu L; Zhang C; Wang X; Ding X; Deng J; Liang H
Clin Transl Oncol; 2016 Mar; 18(3):296-303. PubMed ID: 26260914
[TBL] [Abstract][Full Text] [Related]
8. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer.
Ichikawa D; Koike H; Ikoma H; Ikoma D; Tani N; Otsuji E; Kitamura K; Yamagishi H
Anticancer Res; 2004; 24(4):2477-81. PubMed ID: 15330201
[TBL] [Abstract][Full Text] [Related]
9. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival.
Xu L; Li X; Chu ES; Zhao G; Go MY; Tao Q; Jin H; Zeng Z; Sung JJ; Yu J
Gut; 2012 Jul; 61(7):977-85. PubMed ID: 21917650
[TBL] [Abstract][Full Text] [Related]
11. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer.
Ling ZQ; Lv P; Lu XX; Yu JL; Han J; Ying LS; Zhu X; Zhu WY; Fang XH; Wang S; Wu YC
PLoS One; 2013; 8(6):e67195. PubMed ID: 23826230
[TBL] [Abstract][Full Text] [Related]
12. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
13. AKR1B10, a good prognostic indicator in gastric cancer.
Yao HB; Xu Y; Chen LG; Guan TP; Ma YY; He XJ; Xia YJ; Tao HQ; Shao QS
Eur J Surg Oncol; 2014 Mar; 40(3):318-24. PubMed ID: 24406159
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer.
Kanda M; Shimizu D; Nomoto S; Hibino S; Oya H; Takami H; Kobayashi D; Yamada S; Inokawa Y; Tanaka C; Fujii T; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2014 Aug; 110(2):136-44. PubMed ID: 24700496
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of DNA methylation is associated with tumor stage in gastric cancer.
Oue N; Mitani Y; Motoshita J; Matsumura S; Yoshida K; Kuniyasu H; Nakayama H; Yasui W
Cancer; 2006 Mar; 106(6):1250-9. PubMed ID: 16475210
[TBL] [Abstract][Full Text] [Related]
16. Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis.
Darnton SJ; Hardie LJ; Muc RS; Wild CP; Casson AG
Int J Cancer; 2005 Jun; 115(3):351-8. PubMed ID: 15688381
[TBL] [Abstract][Full Text] [Related]
17. Association Between Tissue Inhibitor of Metalloproteinase-3 Gene Methylation and Gastric Cancer Risk: A Meta-Analysis.
Cao J; Li Z; Yang L; Liu C; Luan X
Genet Test Mol Biomarkers; 2016 Aug; 20(8):427-31. PubMed ID: 27314831
[TBL] [Abstract][Full Text] [Related]
18. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer.
Xu X; Chang X; Li Z; Wang J; Deng P; Zhu X; Liu J; Zhang C; Chen S; Dai D
Cell Oncol (Dordr); 2015 Jun; 38(3):183-94. PubMed ID: 25801783
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of pleiotrophin is a prognostic marker for patients with gastric cancer.
Hu H; Li C; Cai S; Zhu C; Tian Y; Zheng J; Hu J; Chen C; Liu W
Hepatogastroenterology; 2014; 61(133):1478-82. PubMed ID: 25436328
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
